Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital

2014 ◽  
Vol 10 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Paola Poletti ◽  
Valentina Ghilardi ◽  
Luca Livraghi ◽  
Laura Milesi ◽  
Elena Rota Caremoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Current Practice ◽  
Community Hospital ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Eribulin Mesylate ◽  
Heavily Pretreated ◽  
Italian Community

Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study

1999 ◽  
Vol 17 (4) ◽  
pp. 1127-1127 ◽  
Author(s):  
E. Salminen ◽  
M. Bergman ◽  
S. Huhtala ◽  
E. Ekholm
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Dose Reduction ◽  
Cancer Patients ◽  
Dose Level ◽  
Metastatic Breast ◽  
Recommended Dose ◽  
Line Treatment ◽  
Breast Cancer Patients ◽  
Heavily Pretreated

PURPOSE: Patients with metastatic breast cancer, especially those with progression after several prior chemotherapy treatments, need efficient chemotherapy. This study investigates the efficacy and toxicity of docetaxel in metastatic breast cancer patients with previous chemotherapy for metastatic disease. PATIENTS AND METHODS: Thirty-one women (median age, 52 years; range, 40 to 65 years) treated for metastatic breast cancer with docetaxel were included. Eleven patients had one metastatic site, 10 patients had two, and 10 patients had three or more. The planned dose of docetaxel per course was the standard treatment of 100 mg/m2 (or 75 mg/m2 if liver enzyme levels were abnormal) every 3 weeks, given for six or eight cycles. RESULTS: The overall response rate was 48% (three complete responses [CR] and 11 partial responses [PR] ), and the median duration of response was 7 months (range, 2 to 16 months). Twenty patients (65%) experienced fatigue, and 27 patients (87%) had alopecia. Fifteen cases (48%) of grade 4 leukopenia were observed. Edema with a weight gain of 2 to 15 kg was seen in 12 patients (39%), and mucositis occurred in 20 patients (65%). Twenty-three patients (74%) interrupted treatment before reaching the planned number of courses, nine patients owing to progression of cancer and 14 owing to toxicity. Dose reduction was required in 18 (61%) of the patients. Only two patients were able to receive the planned eight courses without dose reduction. CONCLUSION: Docetaxel is highly active in metastatic breast cancer, even as a third-line treatment, and can be considered as an efficient standard option in second-line treatment. The standard recommended dose level of 100 mg/m2 is not feasible in heavily pretreated patients; therefore, for such patients, an initial dose level not exceeding 75 mg/m2 is recommended.

scholarly journals Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program

2019 ◽  
Vol 145 (12) ◽  
pp. 3359-3369 ◽  
Author(s):  
William Jacot ◽  
Pierre‐Etienne Heudel ◽  
Julien Fraisse ◽  
Sophie Gourgou ◽  
Séverine Guiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Life Activity ◽  
Eribulin Mesylate

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

2010 ◽  
Vol 28 (S1) ◽  
pp. 115-120 ◽  
Author(s):  
Ellen B. Kossoff ◽  
Nuttapong Ngamphaiboon ◽  
Thomas J. Laudico ◽  
Tracey L. O’Connor
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Heavily Pretreated

Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

Oncology ◽  
2005 ◽  
Vol 69 (5) ◽  
pp. 408-413 ◽  
Author(s):  
M. Donadio ◽  
M. Ardine ◽  
A. Berruti ◽  
A. Beano ◽  
A. Bottini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Heavily Pretreated ◽  
Weekly Cisplatin

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

2015 ◽  
Vol 11 (3) ◽  
pp. 431-438 ◽  
Author(s):  
Alessandra Fabi ◽  
Luca Moscetti ◽  
Mariangela Ciccarese ◽  
Miriam Caramanti ◽  
Nello Salesi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Biological Feature ◽  
Heavily Pretreated
Sign in / Sign up

Export Citation Format

Share Document